RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement

RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private 
Placement 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: RepliCel Life Sciences Inc. 
TSX VENTURE SYMBOL:  RP
OTCQB SYMBOL:  REPCF 
MAY 21, 2014 
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private
Placement 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 21, 2014) -  
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN OR INTO
THE UNITED STATES 
RepliCel Life Sciences Inc. ("RepliCel" or the "Company")
(TSX VENTURE:RP)(OTCQB:REPCF) is pleased to announce it has completed the
second tranche of its financing announced on March 28, 2014, which consisted of
a non-brokered private placement of 737,000 units (each a "Unit") at
a price of $0.75 per Unit for gross proceeds of $552,750 (the
"Offering"). The total gross proceeds received to date for this
offering is $3,340,625.25 as the Company announced on May 9, 2014 that it
raised $2,787,875.25 in a brokered and non-brokered private placement
financing. Each Unit consists of one common share of the Company (each, a
"Share") and one Share purchase warrant, which will entitle the
holder to purchase one additional Share for a period of two years from the
closing of the private placement at a price of $1.00 per Share during the first
year and $1.25 per Share during the second year. The Company anticipates a
third closing under the same terms. 
In connection with the Offering, the Company issued finder's warrants to
purchase an aggregate of 58,960 Shares at a price of $0.75 per Share for a
period of 24 months and paid a finder's fee of $44,220 to one finder.  
All securities issued in the financing will be subject to a statutory hold
period expiring four months and one day after closing of the financing. None of
the securities issued in the financing have been registered under the United
States Securities Act of 1933, as amended (the "1933 Act"), and none
of them may be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the 1933 Act. This
press release shall not constitute an offer to sell or a solicitation of an
offer to buy nor shall there be any sale of the securities in any state where
such offer, solicitation, or sale would be unlawful.  
About RepliCel Life Sciences 
RepliCel is a clinical stage biopharmaceutical company focused on developing
autologous cell therapies that treat functional cellular deficits. RepliCel
Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon
injuries. RepliCel Hair-01 (RCH-01) is a cellular treatment for androgenetic
alopecia (pattern baldness). Shiseido Company, Limited has an exclusive
geographic license for RCH-01 in certain Asian countries including Japan, China
and South Korea. Both product candidates are based on RepliCel's
innovative technology which utilizes cells isolated from a patient's own
healthy hair follicles to address specific cellular deficits. For additional
information please visit www.replicel.com. 
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as
that term is defined in the policies of the TSX Venture Exchange Inc.) accepts
responsibility for the adequacy or accuracy of this press release. 
This press release contains forward-looking information that involve various
risks and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on current
expectations involving a number of risks and uncertainties and are not
guarantees of future performance of RepliCel. There are numerous risks and
uncertainties that could cause actual results and RepliCel's plans and
objectives to differ materially from those expressed in the forward-looking
information, including: (i) adverse market conditions; (ii) the inability of
RepliCel to complete the private placement at all or on the terms announced; or
(iii) the TSX Venture Exchange not approving further private placements. Actual
results and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on the dates they
are made and are expressly qualified in their entirety by this notice. Except
as required by law, RepliCel does not intend to update these forward-looking
statements. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
RepliCel Life Sciences
David M. Hall
Chief Executive Officer
604-248-8696
or
RepliCel Life Sciences
Tammey George
Director of Communications
604-248-8696
tg@replicel.com
or
INVESTOR CONTACTS:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
858-356-5932 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Trials 
SUBJECT:  FNC 
-0-
-0- May/21/2014 22:42 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.